nodes	percent_of_prediction	percent_of_DWPC	metapath
Vardenafil—CYP3A5—Progesterone—uterine cancer	0.15	0.368	CbGbCtD
Vardenafil—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0881	0.216	CbGbCtD
Vardenafil—CYP3A5—Etoposide—uterine cancer	0.067	0.165	CbGbCtD
Vardenafil—CYP3A4—Progesterone—uterine cancer	0.0583	0.143	CbGbCtD
Vardenafil—CYP3A4—Etoposide—uterine cancer	0.0261	0.0642	CbGbCtD
Vardenafil—CYP3A4—Doxorubicin—uterine cancer	0.0178	0.0438	CbGbCtD
Vardenafil—PDE5A—artery—uterine cancer	0.012	0.131	CbGeAlD
Vardenafil—PDE11A—epithelium—uterine cancer	0.012	0.13	CbGeAlD
Vardenafil—PDE10A—decidua—uterine cancer	0.00737	0.0801	CbGeAlD
Vardenafil—PDE1B—female reproductive system—uterine cancer	0.00574	0.0624	CbGeAlD
Vardenafil—PDE10A—female gonad—uterine cancer	0.00527	0.0573	CbGeAlD
Vardenafil—PDE6G—lymph node—uterine cancer	0.00502	0.0546	CbGeAlD
Vardenafil—PDE5A—epithelium—uterine cancer	0.00456	0.0496	CbGeAlD
Vardenafil—PDE5A—uterine cervix—uterine cancer	0.00452	0.0492	CbGeAlD
Vardenafil—PDE5A—smooth muscle tissue—uterine cancer	0.0044	0.0478	CbGeAlD
Vardenafil—PDE5A—renal system—uterine cancer	0.00423	0.046	CbGeAlD
Vardenafil—PDE5A—female reproductive system—uterine cancer	0.00339	0.0369	CbGeAlD
Vardenafil—PDE10A—lymph node—uterine cancer	0.00339	0.0368	CbGeAlD
Vardenafil—PDE1B—lymph node—uterine cancer	0.00336	0.0365	CbGeAlD
Vardenafil—PDE5A—female gonad—uterine cancer	0.00308	0.0335	CbGeAlD
Vardenafil—PDE5A—vagina—uterine cancer	0.00307	0.0333	CbGeAlD
Vardenafil—PDE5A—lymph node—uterine cancer	0.00198	0.0216	CbGeAlD
Vardenafil—CYP3A5—uterine cervix—uterine cancer	0.00188	0.0204	CbGeAlD
Vardenafil—CYP3A5—renal system—uterine cancer	0.00176	0.0191	CbGeAlD
Vardenafil—CYP3A4—renal system—uterine cancer	0.00132	0.0143	CbGeAlD
Vardenafil—CYP3A5—female gonad—uterine cancer	0.00128	0.0139	CbGeAlD
Vardenafil—CYP3A5—vagina—uterine cancer	0.00127	0.0138	CbGeAlD
Vardenafil—CYP3A4—female reproductive system—uterine cancer	0.00106	0.0115	CbGeAlD
Vardenafil—Hypertonia—Epirubicin—uterine cancer	0.000732	0.00164	CcSEcCtD
Vardenafil—Infection—Dactinomycin—uterine cancer	0.00073	0.00164	CcSEcCtD
Vardenafil—Abnormal vision—Epirubicin—uterine cancer	0.000729	0.00164	CcSEcCtD
Vardenafil—Diarrhoea—Progesterone—uterine cancer	0.000711	0.0016	CcSEcCtD
Vardenafil—Oesophagitis—Doxorubicin—uterine cancer	0.000706	0.00159	CcSEcCtD
Vardenafil—Eye disorder—Etoposide—uterine cancer	0.0007	0.00157	CcSEcCtD
Vardenafil—Flushing—Etoposide—uterine cancer	0.000695	0.00156	CcSEcCtD
Vardenafil—Cardiac disorder—Etoposide—uterine cancer	0.000695	0.00156	CcSEcCtD
Vardenafil—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000694	0.00156	CcSEcCtD
Vardenafil—Dizziness—Progesterone—uterine cancer	0.000687	0.00154	CcSEcCtD
Vardenafil—Angiopathy—Etoposide—uterine cancer	0.000679	0.00152	CcSEcCtD
Vardenafil—Hypertonia—Doxorubicin—uterine cancer	0.000678	0.00152	CcSEcCtD
Vardenafil—Immune system disorder—Etoposide—uterine cancer	0.000676	0.00152	CcSEcCtD
Vardenafil—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000676	0.00152	CcSEcCtD
Vardenafil—Mediastinal disorder—Etoposide—uterine cancer	0.000675	0.00151	CcSEcCtD
Vardenafil—Abnormal vision—Doxorubicin—uterine cancer	0.000674	0.00151	CcSEcCtD
Vardenafil—Eye pain—Epirubicin—uterine cancer	0.000672	0.00151	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000669	0.0015	CcSEcCtD
Vardenafil—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000667	0.0015	CcSEcCtD
Vardenafil—Vomiting—Progesterone—uterine cancer	0.000661	0.00148	CcSEcCtD
Vardenafil—Rash—Progesterone—uterine cancer	0.000656	0.00147	CcSEcCtD
Vardenafil—Dermatitis—Progesterone—uterine cancer	0.000655	0.00147	CcSEcCtD
Vardenafil—Headache—Progesterone—uterine cancer	0.000651	0.00146	CcSEcCtD
Vardenafil—Hot flush—Epirubicin—uterine cancer	0.000648	0.00146	CcSEcCtD
Vardenafil—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000645	0.00145	CcSEcCtD
Vardenafil—Menopausal symptoms—Epirubicin—uterine cancer	0.000643	0.00144	CcSEcCtD
Vardenafil—Back pain—Etoposide—uterine cancer	0.00063	0.00141	CcSEcCtD
Vardenafil—Pain—Dactinomycin—uterine cancer	0.000628	0.00141	CcSEcCtD
Vardenafil—Muscle spasms—Etoposide—uterine cancer	0.000627	0.00141	CcSEcCtD
Vardenafil—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000623	0.0014	CcSEcCtD
Vardenafil—Eye pain—Doxorubicin—uterine cancer	0.000622	0.0014	CcSEcCtD
Vardenafil—Nausea—Progesterone—uterine cancer	0.000618	0.00139	CcSEcCtD
Vardenafil—Feeling abnormal—Dactinomycin—uterine cancer	0.000606	0.00136	CcSEcCtD
Vardenafil—Ill-defined disorder—Etoposide—uterine cancer	0.000605	0.00136	CcSEcCtD
Vardenafil—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000601	0.00135	CcSEcCtD
Vardenafil—Hot flush—Doxorubicin—uterine cancer	0.0006	0.00135	CcSEcCtD
Vardenafil—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000599	0.00134	CcSEcCtD
Vardenafil—Menopausal symptoms—Doxorubicin—uterine cancer	0.000595	0.00133	CcSEcCtD
Vardenafil—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000594	0.00133	CcSEcCtD
Vardenafil—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000593	0.00133	CcSEcCtD
Vardenafil—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00059	0.00132	CcSEcCtD
Vardenafil—Malaise—Etoposide—uterine cancer	0.000588	0.00132	CcSEcCtD
Vardenafil—Face oedema—Epirubicin—uterine cancer	0.000586	0.00131	CcSEcCtD
Vardenafil—Vertigo—Etoposide—uterine cancer	0.000585	0.00131	CcSEcCtD
Vardenafil—Abdominal pain—Dactinomycin—uterine cancer	0.000581	0.0013	CcSEcCtD
Vardenafil—Loss of consciousness—Etoposide—uterine cancer	0.000573	0.00129	CcSEcCtD
Vardenafil—Blood creatinine increased—Epirubicin—uterine cancer	0.000568	0.00128	CcSEcCtD
Vardenafil—Convulsion—Etoposide—uterine cancer	0.000565	0.00127	CcSEcCtD
Vardenafil—Liver function test abnormal—Epirubicin—uterine cancer	0.00056	0.00126	CcSEcCtD
Vardenafil—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00056	0.00126	CcSEcCtD
Vardenafil—Chest pain—Etoposide—uterine cancer	0.000555	0.00125	CcSEcCtD
Vardenafil—Abdominal pain upper—Epirubicin—uterine cancer	0.000554	0.00124	CcSEcCtD
Vardenafil—Orthostatic hypotension—Epirubicin—uterine cancer	0.000554	0.00124	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000551	0.00124	CcSEcCtD
Vardenafil—Discomfort—Etoposide—uterine cancer	0.000548	0.00123	CcSEcCtD
Vardenafil—Breast disorder—Epirubicin—uterine cancer	0.000548	0.00123	CcSEcCtD
Vardenafil—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000546	0.00123	CcSEcCtD
Vardenafil—Face oedema—Doxorubicin—uterine cancer	0.000542	0.00122	CcSEcCtD
Vardenafil—Hypersensitivity—Dactinomycin—uterine cancer	0.000541	0.00122	CcSEcCtD
Vardenafil—Gastritis—Epirubicin—uterine cancer	0.000537	0.0012	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000535	0.0012	CcSEcCtD
Vardenafil—Anaphylactic shock—Etoposide—uterine cancer	0.000532	0.00119	CcSEcCtD
Vardenafil—Infection—Etoposide—uterine cancer	0.000528	0.00119	CcSEcCtD
Vardenafil—Asthenia—Dactinomycin—uterine cancer	0.000527	0.00118	CcSEcCtD
Vardenafil—Blood creatinine increased—Doxorubicin—uterine cancer	0.000526	0.00118	CcSEcCtD
Vardenafil—Influenza—Epirubicin—uterine cancer	0.000524	0.00118	CcSEcCtD
Vardenafil—Dysphagia—Epirubicin—uterine cancer	0.000524	0.00118	CcSEcCtD
Vardenafil—Tachycardia—Etoposide—uterine cancer	0.000519	0.00117	CcSEcCtD
Vardenafil—Liver function test abnormal—Doxorubicin—uterine cancer	0.000518	0.00116	CcSEcCtD
Vardenafil—Skin disorder—Etoposide—uterine cancer	0.000517	0.00116	CcSEcCtD
Vardenafil—Hyperhidrosis—Etoposide—uterine cancer	0.000514	0.00115	CcSEcCtD
Vardenafil—Abdominal pain upper—Doxorubicin—uterine cancer	0.000513	0.00115	CcSEcCtD
Vardenafil—Orthostatic hypotension—Doxorubicin—uterine cancer	0.000513	0.00115	CcSEcCtD
Vardenafil—Angina pectoris—Epirubicin—uterine cancer	0.000511	0.00115	CcSEcCtD
Vardenafil—Breast disorder—Doxorubicin—uterine cancer	0.000507	0.00114	CcSEcCtD
Vardenafil—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000505	0.00113	CcSEcCtD
Vardenafil—Diarrhoea—Dactinomycin—uterine cancer	0.000503	0.00113	CcSEcCtD
Vardenafil—Hypotension—Etoposide—uterine cancer	0.000497	0.00112	CcSEcCtD
Vardenafil—Gastritis—Doxorubicin—uterine cancer	0.000497	0.00111	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000495	0.00111	CcSEcCtD
Vardenafil—Influenza—Doxorubicin—uterine cancer	0.000485	0.00109	CcSEcCtD
Vardenafil—Dysphagia—Doxorubicin—uterine cancer	0.000485	0.00109	CcSEcCtD
Vardenafil—Photosensitivity reaction—Epirubicin—uterine cancer	0.000479	0.00107	CcSEcCtD
Vardenafil—Paraesthesia—Etoposide—uterine cancer	0.000478	0.00107	CcSEcCtD
Vardenafil—Dyspnoea—Etoposide—uterine cancer	0.000474	0.00106	CcSEcCtD
Vardenafil—Somnolence—Etoposide—uterine cancer	0.000473	0.00106	CcSEcCtD
Vardenafil—Angina pectoris—Doxorubicin—uterine cancer	0.000473	0.00106	CcSEcCtD
Vardenafil—Infestation—Epirubicin—uterine cancer	0.000467	0.00105	CcSEcCtD
Vardenafil—Infestation NOS—Epirubicin—uterine cancer	0.000467	0.00105	CcSEcCtD
Vardenafil—Vomiting—Dactinomycin—uterine cancer	0.000467	0.00105	CcSEcCtD
Vardenafil—Rash—Dactinomycin—uterine cancer	0.000463	0.00104	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Etoposide—uterine cancer	0.000459	0.00103	CcSEcCtD
Vardenafil—Pain—Etoposide—uterine cancer	0.000455	0.00102	CcSEcCtD
Vardenafil—Conjunctivitis—Epirubicin—uterine cancer	0.000454	0.00102	CcSEcCtD
Vardenafil—Sweating—Epirubicin—uterine cancer	0.000448	0.00101	CcSEcCtD
Vardenafil—Haematuria—Epirubicin—uterine cancer	0.000446	0.001	CcSEcCtD
Vardenafil—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000443	0.000994	CcSEcCtD
Vardenafil—Hepatobiliary disease—Epirubicin—uterine cancer	0.000442	0.000992	CcSEcCtD
Vardenafil—Epistaxis—Epirubicin—uterine cancer	0.000441	0.00099	CcSEcCtD
Vardenafil—Sinusitis—Epirubicin—uterine cancer	0.000439	0.000984	CcSEcCtD
Vardenafil—Feeling abnormal—Etoposide—uterine cancer	0.000438	0.000984	CcSEcCtD
Vardenafil—Nausea—Dactinomycin—uterine cancer	0.000436	0.00098	CcSEcCtD
Vardenafil—Gastrointestinal pain—Etoposide—uterine cancer	0.000435	0.000976	CcSEcCtD
Vardenafil—Infestation NOS—Doxorubicin—uterine cancer	0.000433	0.000971	CcSEcCtD
Vardenafil—Infestation—Doxorubicin—uterine cancer	0.000433	0.000971	CcSEcCtD
Vardenafil—Haemoglobin—Epirubicin—uterine cancer	0.000422	0.000947	CcSEcCtD
Vardenafil—Rhinitis—Epirubicin—uterine cancer	0.000421	0.000944	CcSEcCtD
Vardenafil—Abdominal pain—Etoposide—uterine cancer	0.00042	0.000944	CcSEcCtD
Vardenafil—Conjunctivitis—Doxorubicin—uterine cancer	0.00042	0.000944	CcSEcCtD
Vardenafil—Haemorrhage—Epirubicin—uterine cancer	0.00042	0.000942	CcSEcCtD
Vardenafil—Hypoaesthesia—Epirubicin—uterine cancer	0.000418	0.000937	CcSEcCtD
Vardenafil—Pharyngitis—Epirubicin—uterine cancer	0.000416	0.000935	CcSEcCtD
Vardenafil—Sweating—Doxorubicin—uterine cancer	0.000415	0.000931	CcSEcCtD
Vardenafil—Urinary tract disorder—Epirubicin—uterine cancer	0.000414	0.00093	CcSEcCtD
Vardenafil—Haematuria—Doxorubicin—uterine cancer	0.000412	0.000926	CcSEcCtD
Vardenafil—Connective tissue disorder—Epirubicin—uterine cancer	0.000412	0.000926	CcSEcCtD
Vardenafil—Urethral disorder—Epirubicin—uterine cancer	0.000411	0.000923	CcSEcCtD
Vardenafil—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000409	0.000918	CcSEcCtD
Vardenafil—Epistaxis—Doxorubicin—uterine cancer	0.000408	0.000916	CcSEcCtD
Vardenafil—Sinusitis—Doxorubicin—uterine cancer	0.000406	0.000911	CcSEcCtD
Vardenafil—Visual impairment—Epirubicin—uterine cancer	0.000404	0.000908	CcSEcCtD
Vardenafil—Eye disorder—Epirubicin—uterine cancer	0.000392	0.00088	CcSEcCtD
Vardenafil—Hypersensitivity—Etoposide—uterine cancer	0.000392	0.000879	CcSEcCtD
Vardenafil—Tinnitus—Epirubicin—uterine cancer	0.000391	0.000878	CcSEcCtD
Vardenafil—Haemoglobin—Doxorubicin—uterine cancer	0.00039	0.000876	CcSEcCtD
Vardenafil—Cardiac disorder—Epirubicin—uterine cancer	0.000389	0.000874	CcSEcCtD
Vardenafil—Flushing—Epirubicin—uterine cancer	0.000389	0.000874	CcSEcCtD
Vardenafil—Rhinitis—Doxorubicin—uterine cancer	0.000389	0.000874	CcSEcCtD
Vardenafil—Haemorrhage—Doxorubicin—uterine cancer	0.000388	0.000871	CcSEcCtD
Vardenafil—Hypoaesthesia—Doxorubicin—uterine cancer	0.000386	0.000867	CcSEcCtD
Vardenafil—Pharyngitis—Doxorubicin—uterine cancer	0.000385	0.000865	CcSEcCtD
Vardenafil—Urinary tract disorder—Doxorubicin—uterine cancer	0.000383	0.000861	CcSEcCtD
Vardenafil—Asthenia—Etoposide—uterine cancer	0.000382	0.000856	CcSEcCtD
Vardenafil—Connective tissue disorder—Doxorubicin—uterine cancer	0.000382	0.000856	CcSEcCtD
Vardenafil—Angiopathy—Epirubicin—uterine cancer	0.000381	0.000854	CcSEcCtD
Vardenafil—Urethral disorder—Doxorubicin—uterine cancer	0.000381	0.000854	CcSEcCtD
Vardenafil—Immune system disorder—Epirubicin—uterine cancer	0.000379	0.000851	CcSEcCtD
Vardenafil—Mediastinal disorder—Epirubicin—uterine cancer	0.000378	0.000849	CcSEcCtD
Vardenafil—Pruritus—Etoposide—uterine cancer	0.000376	0.000845	CcSEcCtD
Vardenafil—Visual impairment—Doxorubicin—uterine cancer	0.000374	0.00084	CcSEcCtD
Vardenafil—Mental disorder—Epirubicin—uterine cancer	0.000368	0.000825	CcSEcCtD
Vardenafil—Erythema—Epirubicin—uterine cancer	0.000365	0.00082	CcSEcCtD
Vardenafil—Diarrhoea—Etoposide—uterine cancer	0.000364	0.000817	CcSEcCtD
Vardenafil—Eye disorder—Doxorubicin—uterine cancer	0.000363	0.000814	CcSEcCtD
Vardenafil—Tinnitus—Doxorubicin—uterine cancer	0.000362	0.000813	CcSEcCtD
Vardenafil—Flushing—Doxorubicin—uterine cancer	0.00036	0.000809	CcSEcCtD
Vardenafil—Cardiac disorder—Doxorubicin—uterine cancer	0.00036	0.000809	CcSEcCtD
Vardenafil—Back pain—Epirubicin—uterine cancer	0.000353	0.000793	CcSEcCtD
Vardenafil—Angiopathy—Doxorubicin—uterine cancer	0.000352	0.000791	CcSEcCtD
Vardenafil—Dizziness—Etoposide—uterine cancer	0.000352	0.000789	CcSEcCtD
Vardenafil—Muscle spasms—Epirubicin—uterine cancer	0.000351	0.000788	CcSEcCtD
Vardenafil—Immune system disorder—Doxorubicin—uterine cancer	0.000351	0.000787	CcSEcCtD
Vardenafil—Mediastinal disorder—Doxorubicin—uterine cancer	0.00035	0.000785	CcSEcCtD
Vardenafil—Vision blurred—Epirubicin—uterine cancer	0.000344	0.000773	CcSEcCtD
Vardenafil—Mental disorder—Doxorubicin—uterine cancer	0.00034	0.000763	CcSEcCtD
Vardenafil—Ill-defined disorder—Epirubicin—uterine cancer	0.000339	0.000761	CcSEcCtD
Vardenafil—Vomiting—Etoposide—uterine cancer	0.000338	0.000759	CcSEcCtD
Vardenafil—Erythema—Doxorubicin—uterine cancer	0.000338	0.000759	CcSEcCtD
Vardenafil—Rash—Etoposide—uterine cancer	0.000335	0.000753	CcSEcCtD
Vardenafil—Dermatitis—Etoposide—uterine cancer	0.000335	0.000752	CcSEcCtD
Vardenafil—Headache—Etoposide—uterine cancer	0.000333	0.000748	CcSEcCtD
Vardenafil—Malaise—Epirubicin—uterine cancer	0.000329	0.000739	CcSEcCtD
Vardenafil—Vertigo—Epirubicin—uterine cancer	0.000328	0.000737	CcSEcCtD
Vardenafil—Syncope—Epirubicin—uterine cancer	0.000328	0.000735	CcSEcCtD
Vardenafil—Back pain—Doxorubicin—uterine cancer	0.000327	0.000734	CcSEcCtD
Vardenafil—Muscle spasms—Doxorubicin—uterine cancer	0.000325	0.000729	CcSEcCtD
Vardenafil—Palpitations—Epirubicin—uterine cancer	0.000323	0.000725	CcSEcCtD
Vardenafil—Loss of consciousness—Epirubicin—uterine cancer	0.000321	0.000721	CcSEcCtD
Vardenafil—Vision blurred—Doxorubicin—uterine cancer	0.000319	0.000715	CcSEcCtD
Vardenafil—Convulsion—Epirubicin—uterine cancer	0.000316	0.00071	CcSEcCtD
Vardenafil—Nausea—Etoposide—uterine cancer	0.000316	0.000709	CcSEcCtD
Vardenafil—Ill-defined disorder—Doxorubicin—uterine cancer	0.000314	0.000704	CcSEcCtD
Vardenafil—Arthralgia—Epirubicin—uterine cancer	0.000311	0.000698	CcSEcCtD
Vardenafil—Chest pain—Epirubicin—uterine cancer	0.000311	0.000698	CcSEcCtD
Vardenafil—Myalgia—Epirubicin—uterine cancer	0.000311	0.000698	CcSEcCtD
Vardenafil—Anxiety—Epirubicin—uterine cancer	0.00031	0.000696	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000309	0.000693	CcSEcCtD
Vardenafil—Discomfort—Epirubicin—uterine cancer	0.000307	0.00069	CcSEcCtD
Vardenafil—Malaise—Doxorubicin—uterine cancer	0.000305	0.000684	CcSEcCtD
Vardenafil—Dry mouth—Epirubicin—uterine cancer	0.000304	0.000683	CcSEcCtD
Vardenafil—Vertigo—Doxorubicin—uterine cancer	0.000304	0.000682	CcSEcCtD
Vardenafil—Syncope—Doxorubicin—uterine cancer	0.000303	0.00068	CcSEcCtD
Vardenafil—Palpitations—Doxorubicin—uterine cancer	0.000299	0.00067	CcSEcCtD
Vardenafil—Anaphylactic shock—Epirubicin—uterine cancer	0.000298	0.000669	CcSEcCtD
Vardenafil—Loss of consciousness—Doxorubicin—uterine cancer	0.000297	0.000667	CcSEcCtD
Vardenafil—Infection—Epirubicin—uterine cancer	0.000296	0.000665	CcSEcCtD
Vardenafil—Shock—Epirubicin—uterine cancer	0.000293	0.000658	CcSEcCtD
Vardenafil—Convulsion—Doxorubicin—uterine cancer	0.000293	0.000657	CcSEcCtD
Vardenafil—Nervous system disorder—Epirubicin—uterine cancer	0.000292	0.000656	CcSEcCtD
Vardenafil—Tachycardia—Epirubicin—uterine cancer	0.000291	0.000653	CcSEcCtD
Vardenafil—Skin disorder—Epirubicin—uterine cancer	0.00029	0.00065	CcSEcCtD
Vardenafil—Hyperhidrosis—Epirubicin—uterine cancer	0.000288	0.000647	CcSEcCtD
Vardenafil—Chest pain—Doxorubicin—uterine cancer	0.000288	0.000646	CcSEcCtD
Vardenafil—Myalgia—Doxorubicin—uterine cancer	0.000288	0.000646	CcSEcCtD
Vardenafil—Arthralgia—Doxorubicin—uterine cancer	0.000288	0.000646	CcSEcCtD
Vardenafil—Anxiety—Doxorubicin—uterine cancer	0.000287	0.000644	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000286	0.000641	CcSEcCtD
Vardenafil—Discomfort—Doxorubicin—uterine cancer	0.000284	0.000638	CcSEcCtD
Vardenafil—Dry mouth—Doxorubicin—uterine cancer	0.000281	0.000632	CcSEcCtD
Vardenafil—Hypotension—Epirubicin—uterine cancer	0.000279	0.000625	CcSEcCtD
Vardenafil—Anaphylactic shock—Doxorubicin—uterine cancer	0.000276	0.000619	CcSEcCtD
Vardenafil—Infection—Doxorubicin—uterine cancer	0.000274	0.000615	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000272	0.00061	CcSEcCtD
Vardenafil—Shock—Doxorubicin—uterine cancer	0.000271	0.000609	CcSEcCtD
Vardenafil—Nervous system disorder—Doxorubicin—uterine cancer	0.000271	0.000607	CcSEcCtD
Vardenafil—Insomnia—Epirubicin—uterine cancer	0.00027	0.000605	CcSEcCtD
Vardenafil—Tachycardia—Doxorubicin—uterine cancer	0.000269	0.000604	CcSEcCtD
Vardenafil—Skin disorder—Doxorubicin—uterine cancer	0.000268	0.000601	CcSEcCtD
Vardenafil—Paraesthesia—Epirubicin—uterine cancer	0.000268	0.000601	CcSEcCtD
Vardenafil—Hyperhidrosis—Doxorubicin—uterine cancer	0.000267	0.000599	CcSEcCtD
Vardenafil—Dyspnoea—Epirubicin—uterine cancer	0.000266	0.000597	CcSEcCtD
Vardenafil—Somnolence—Epirubicin—uterine cancer	0.000265	0.000595	CcSEcCtD
Vardenafil—Dyspepsia—Epirubicin—uterine cancer	0.000262	0.000589	CcSEcCtD
Vardenafil—Hypotension—Doxorubicin—uterine cancer	0.000258	0.000579	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000257	0.000578	CcSEcCtD
Vardenafil—Pain—Epirubicin—uterine cancer	0.000255	0.000572	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000251	0.000564	CcSEcCtD
Vardenafil—Insomnia—Doxorubicin—uterine cancer	0.000249	0.00056	CcSEcCtD
Vardenafil—Paraesthesia—Doxorubicin—uterine cancer	0.000248	0.000556	CcSEcCtD
Vardenafil—Dyspnoea—Doxorubicin—uterine cancer	0.000246	0.000552	CcSEcCtD
Vardenafil—Feeling abnormal—Epirubicin—uterine cancer	0.000246	0.000551	CcSEcCtD
Vardenafil—Somnolence—Doxorubicin—uterine cancer	0.000245	0.00055	CcSEcCtD
Vardenafil—Gastrointestinal pain—Epirubicin—uterine cancer	0.000244	0.000547	CcSEcCtD
Vardenafil—Dyspepsia—Doxorubicin—uterine cancer	0.000243	0.000545	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000238	0.000535	CcSEcCtD
Vardenafil—Pain—Doxorubicin—uterine cancer	0.000236	0.000529	CcSEcCtD
Vardenafil—Abdominal pain—Epirubicin—uterine cancer	0.000236	0.000529	CcSEcCtD
Vardenafil—Feeling abnormal—Doxorubicin—uterine cancer	0.000227	0.00051	CcSEcCtD
Vardenafil—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000226	0.000506	CcSEcCtD
Vardenafil—Hypersensitivity—Epirubicin—uterine cancer	0.00022	0.000493	CcSEcCtD
Vardenafil—Abdominal pain—Doxorubicin—uterine cancer	0.000218	0.000489	CcSEcCtD
Vardenafil—Asthenia—Epirubicin—uterine cancer	0.000214	0.00048	CcSEcCtD
Vardenafil—Pruritus—Epirubicin—uterine cancer	0.000211	0.000473	CcSEcCtD
Vardenafil—Diarrhoea—Epirubicin—uterine cancer	0.000204	0.000458	CcSEcCtD
Vardenafil—Hypersensitivity—Doxorubicin—uterine cancer	0.000203	0.000456	CcSEcCtD
Vardenafil—Asthenia—Doxorubicin—uterine cancer	0.000198	0.000444	CcSEcCtD
Vardenafil—Dizziness—Epirubicin—uterine cancer	0.000197	0.000442	CcSEcCtD
Vardenafil—Pruritus—Doxorubicin—uterine cancer	0.000195	0.000438	CcSEcCtD
Vardenafil—Vomiting—Epirubicin—uterine cancer	0.00019	0.000425	CcSEcCtD
Vardenafil—Diarrhoea—Doxorubicin—uterine cancer	0.000189	0.000424	CcSEcCtD
Vardenafil—Rash—Epirubicin—uterine cancer	0.000188	0.000422	CcSEcCtD
Vardenafil—Dermatitis—Epirubicin—uterine cancer	0.000188	0.000422	CcSEcCtD
Vardenafil—Headache—Epirubicin—uterine cancer	0.000187	0.000419	CcSEcCtD
Vardenafil—Dizziness—Doxorubicin—uterine cancer	0.000182	0.000409	CcSEcCtD
Vardenafil—Nausea—Epirubicin—uterine cancer	0.000177	0.000397	CcSEcCtD
Vardenafil—Vomiting—Doxorubicin—uterine cancer	0.000175	0.000394	CcSEcCtD
Vardenafil—Rash—Doxorubicin—uterine cancer	0.000174	0.00039	CcSEcCtD
Vardenafil—Dermatitis—Doxorubicin—uterine cancer	0.000174	0.00039	CcSEcCtD
Vardenafil—Headache—Doxorubicin—uterine cancer	0.000173	0.000388	CcSEcCtD
Vardenafil—Nausea—Doxorubicin—uterine cancer	0.000164	0.000368	CcSEcCtD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—KRAS—uterine cancer	9.95e-05	0.00179	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—IGF1R—uterine cancer	9.87e-05	0.00178	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—PIK3CA—uterine cancer	9.86e-05	0.00178	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—CXCL8—uterine cancer	9.82e-05	0.00177	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—SOCS3—uterine cancer	9.71e-05	0.00175	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—AKT1—uterine cancer	9.68e-05	0.00174	CbGpPWpGaD
Vardenafil—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	9.57e-05	0.00172	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—KRAS—uterine cancer	9.56e-05	0.00172	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—KRAS—uterine cancer	9.56e-05	0.00172	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—HRAS—uterine cancer	9.55e-05	0.00172	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—HRAS—uterine cancer	9.55e-05	0.00172	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—TP53—uterine cancer	9.54e-05	0.00172	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—INHBA—uterine cancer	9.48e-05	0.00171	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—HRAS—uterine cancer	9.46e-05	0.0017	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—SOCS3—uterine cancer	9.46e-05	0.0017	CbGpPWpGaD
Vardenafil—PDE1B—Disease—AKR1C3—uterine cancer	9.38e-05	0.00169	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—HRAS—uterine cancer	9.38e-05	0.00169	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—HRAS—uterine cancer	9.34e-05	0.00168	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CDKN2B—uterine cancer	9.29e-05	0.00167	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—SMAD3—uterine cancer	9.28e-05	0.00167	CbGpPWpGaD
Vardenafil—PDE1B—Disease—HMGA1—uterine cancer	9.15e-05	0.00165	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—PIK3CA—uterine cancer	9.14e-05	0.00165	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—HRAS—uterine cancer	9.12e-05	0.00164	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signal transduction—AKT1—uterine cancer	9.09e-05	0.00164	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—FBXW7—uterine cancer	9.06e-05	0.00163	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CDKN2B—uterine cancer	9.06e-05	0.00163	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—AKT1—uterine cancer	9.05e-05	0.00163	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—IGF1R—uterine cancer	9.02e-05	0.00163	CbGpPWpGaD
Vardenafil—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	9.01e-05	0.00162	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—AKT1—uterine cancer	9e-05	0.00162	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—AKT1—uterine cancer	8.96e-05	0.00161	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—CXCL8—uterine cancer	8.92e-05	0.00161	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—NRAS—uterine cancer	8.89e-05	0.0016	CbGpPWpGaD
Vardenafil—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	8.88e-05	0.0016	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—FGFR2—uterine cancer	8.85e-05	0.00159	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—IGF1R—uterine cancer	8.79e-05	0.00158	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—PIK3CA—uterine cancer	8.79e-05	0.00158	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—PIK3CA—uterine cancer	8.79e-05	0.00158	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—CXCL8—uterine cancer	8.75e-05	0.00158	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—AKR1C1—uterine cancer	8.54e-05	0.00154	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—TP53—uterine cancer	8.5e-05	0.00153	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—TP53—uterine cancer	8.5e-05	0.00153	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—SMAD3—uterine cancer	8.48e-05	0.00153	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—HRAS—uterine cancer	8.46e-05	0.00152	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—AKT1—uterine cancer	8.43e-05	0.00152	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—AKT1—uterine cancer	8.43e-05	0.00152	CbGpPWpGaD
Vardenafil—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	8.39e-05	0.00151	CbGpPWpGaD
Vardenafil—PDE1B—Disease—FBXW7—uterine cancer	8.36e-05	0.00151	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—AKT1—uterine cancer	8.35e-05	0.0015	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—AKT1—uterine cancer	8.28e-05	0.00149	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—SMAD3—uterine cancer	8.27e-05	0.00149	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—AKT1—uterine cancer	8.24e-05	0.00149	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—HRAS—uterine cancer	8.13e-05	0.00146	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—HRAS—uterine cancer	8.13e-05	0.00146	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—FGFR2—uterine cancer	8.09e-05	0.00146	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—AKT1—uterine cancer	8.05e-05	0.00145	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—CXCL8—uterine cancer	7.95e-05	0.00143	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—FGFR2—uterine cancer	7.89e-05	0.00142	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—SRD5A2—uterine cancer	7.66e-05	0.00138	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—NDUFB11—uterine cancer	7.66e-05	0.00138	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—KRAS—uterine cancer	7.65e-05	0.00138	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—ESR1—uterine cancer	7.57e-05	0.00136	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—AKT1—uterine cancer	7.47e-05	0.00134	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—SOCS3—uterine cancer	7.41e-05	0.00134	CbGpPWpGaD
Vardenafil—PDE6G—Disease—ERBB2—uterine cancer	7.26e-05	0.00131	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—AKT1—uterine cancer	7.18e-05	0.00129	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—AKT1—uterine cancer	7.18e-05	0.00129	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—NRAS—uterine cancer	7.16e-05	0.00129	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—PIK3CA—uterine cancer	7.03e-05	0.00127	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—ESR1—uterine cancer	6.92e-05	0.00125	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—ESR1—uterine cancer	6.75e-05	0.00122	CbGpPWpGaD
Vardenafil—PDE6G—Disease—CDKN1B—uterine cancer	6.72e-05	0.00121	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—ERBB2—uterine cancer	6.66e-05	0.0012	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CCL2—uterine cancer	6.66e-05	0.0012	CbGpPWpGaD
Vardenafil—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	6.63e-05	0.00119	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—AKR1C3—uterine cancer	6.57e-05	0.00118	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CDKN2B—uterine cancer	6.55e-05	0.00118	CbGpPWpGaD
Vardenafil—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	6.54e-05	0.00118	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—HRAS—uterine cancer	6.5e-05	0.00117	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PGR—uterine cancer	6.4e-05	0.00115	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—NRAS—uterine cancer	6.38e-05	0.00115	CbGpPWpGaD
Vardenafil—PDE6G—Disease—CTNNB1—uterine cancer	6.35e-05	0.00114	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—PIK3CA—uterine cancer	6.23e-05	0.00112	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PTEN—uterine cancer	6.19e-05	0.00111	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—FGFR2—uterine cancer	6.18e-05	0.00111	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—CDKN1B—uterine cancer	6.17e-05	0.00111	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—KRAS—uterine cancer	6.16e-05	0.00111	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—YWHAE—uterine cancer	6.11e-05	0.0011	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CCL2—uterine cancer	6.1e-05	0.0011	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—EP300—uterine cancer	6.02e-05	0.00108	CbGpPWpGaD
Vardenafil—PDE1B—Disease—SMAD3—uterine cancer	5.98e-05	0.00108	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CCL2—uterine cancer	5.94e-05	0.00107	CbGpPWpGaD
Vardenafil—PDE6G—Disease—EP300—uterine cancer	5.9e-05	0.00106	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—FBXW7—uterine cancer	5.86e-05	0.00106	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—CTNNB1—uterine cancer	5.83e-05	0.00105	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—AKT1—uterine cancer	5.74e-05	0.00103	CbGpPWpGaD
Vardenafil—PDE1B—Disease—FGFR2—uterine cancer	5.71e-05	0.00103	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—VEGFA—uterine cancer	5.7e-05	0.00103	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—PTEN—uterine cancer	5.68e-05	0.00102	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—PIK3CA—uterine cancer	5.66e-05	0.00102	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—NRAS—uterine cancer	5.63e-05	0.00101	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—ERBB2—uterine cancer	5.56e-05	0.001	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—PIK3CA—uterine cancer	5.55e-05	0.001	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—AKR1B1—uterine cancer	5.54e-05	0.000998	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—STAR—uterine cancer	5.54e-05	0.000998	CbGpPWpGaD
Vardenafil—PDE6G—Disease—NRAS—uterine cancer	5.52e-05	0.000994	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MTHFR—uterine cancer	5.49e-05	0.00099	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—KRAS—uterine cancer	5.49e-05	0.000989	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—EP300—uterine cancer	5.42e-05	0.000976	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CXCL8—uterine cancer	5.27e-05	0.000949	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—HRAS—uterine cancer	5.23e-05	0.000943	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CDKN1B—uterine cancer	5.15e-05	0.000927	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—STK11—uterine cancer	5.12e-05	0.000922	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—CCL2—uterine cancer	5.1e-05	0.000918	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—AKT1—uterine cancer	5.09e-05	0.000917	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—ERBB2—uterine cancer	5.08e-05	0.000915	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—NRAS—uterine cancer	5.07e-05	0.000913	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—PIK3CA—uterine cancer	5.04e-05	0.000908	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—ERBB2—uterine cancer	4.95e-05	0.000892	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CTNNB1—uterine cancer	4.86e-05	0.000876	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—KRAS—uterine cancer	4.85e-05	0.000873	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CXCL8—uterine cancer	4.82e-05	0.000868	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—SOCS3—uterine cancer	4.79e-05	0.000864	CbGpPWpGaD
Vardenafil—PDE6G—Disease—KRAS—uterine cancer	4.75e-05	0.000856	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PTEN—uterine cancer	4.74e-05	0.000853	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CDKN1B—uterine cancer	4.71e-05	0.000848	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CXCL8—uterine cancer	4.7e-05	0.000846	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—HRAS—uterine cancer	4.67e-05	0.00084	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—AKT1—uterine cancer	4.62e-05	0.000833	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CDH1—uterine cancer	4.6e-05	0.000829	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CDKN2B—uterine cancer	4.59e-05	0.000827	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CDKN1B—uterine cancer	4.59e-05	0.000826	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—AKT1—uterine cancer	4.54e-05	0.000817	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—EP300—uterine cancer	4.52e-05	0.000814	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—IGF1R—uterine cancer	4.46e-05	0.000803	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—PIK3CA—uterine cancer	4.45e-05	0.000802	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CTNNB1—uterine cancer	4.45e-05	0.000801	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—CXCL8—uterine cancer	4.44e-05	0.000799	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PIK3CA—uterine cancer	4.37e-05	0.000786	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—KRAS—uterine cancer	4.36e-05	0.000786	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—POLD1—uterine cancer	4.35e-05	0.000783	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PTEN—uterine cancer	4.33e-05	0.000781	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CTNNB1—uterine cancer	4.33e-05	0.00078	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—TP53—uterine cancer	4.31e-05	0.000776	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—VEGFA—uterine cancer	4.28e-05	0.000771	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—NRAS—uterine cancer	4.23e-05	0.000761	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PTEN—uterine cancer	4.22e-05	0.000761	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—SMAD3—uterine cancer	4.19e-05	0.000755	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—EP300—uterine cancer	4.13e-05	0.000744	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—HRAS—uterine cancer	4.12e-05	0.000742	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—AKT1—uterine cancer	4.12e-05	0.000742	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—AKR1C1—uterine cancer	4.07e-05	0.000732	CbGpPWpGaD
Vardenafil—PDE6G—Disease—HRAS—uterine cancer	4.04e-05	0.000728	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—CXCL8—uterine cancer	4.03e-05	0.000726	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—EP300—uterine cancer	4.03e-05	0.000725	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—PIK3CA—uterine cancer	4.01e-05	0.000722	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—FGFR2—uterine cancer	4e-05	0.00072	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—VEGFA—uterine cancer	3.91e-05	0.000705	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—ERBB2—uterine cancer	3.88e-05	0.000699	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—NRAS—uterine cancer	3.87e-05	0.000696	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—VEGFA—uterine cancer	3.81e-05	0.000687	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—NRAS—uterine cancer	3.77e-05	0.000679	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—HRAS—uterine cancer	3.71e-05	0.000668	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—AKT1—uterine cancer	3.64e-05	0.000655	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—KRAS—uterine cancer	3.64e-05	0.000655	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—RRM2—uterine cancer	3.62e-05	0.000653	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CDKN1B—uterine cancer	3.6e-05	0.000648	CbGpPWpGaD
Vardenafil—PDE1B—Disease—ERBB2—uterine cancer	3.58e-05	0.000646	CbGpPWpGaD
Vardenafil—PDE6G—Disease—AKT1—uterine cancer	3.57e-05	0.000642	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—NDUFB11—uterine cancer	3.56e-05	0.000642	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—SRD5A2—uterine cancer	3.56e-05	0.000642	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—DCN—uterine cancer	3.52e-05	0.000634	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—ESR1—uterine cancer	3.42e-05	0.000616	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CTNNB1—uterine cancer	3.4e-05	0.000612	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PIK3CA—uterine cancer	3.34e-05	0.000602	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—KRAS—uterine cancer	3.33e-05	0.000599	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CDKN1B—uterine cancer	3.32e-05	0.000598	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—CYP11A1—uterine cancer	3.31e-05	0.000597	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PTEN—uterine cancer	3.31e-05	0.000596	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—AKT1—uterine cancer	3.28e-05	0.00059	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—KRAS—uterine cancer	3.24e-05	0.000584	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TP53—uterine cancer	3.23e-05	0.000582	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—NRAS—uterine cancer	3.23e-05	0.000582	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—EP300—uterine cancer	3.16e-05	0.000569	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CTNNB1—uterine cancer	3.14e-05	0.000565	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—AKR1C3—uterine cancer	3.13e-05	0.000564	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—HRAS—uterine cancer	3.09e-05	0.000557	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PIK3CA—uterine cancer	3.06e-05	0.000551	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PTEN—uterine cancer	3.06e-05	0.000551	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CCL2—uterine cancer	3.01e-05	0.000542	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PIK3CA—uterine cancer	2.98e-05	0.000537	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TP53—uterine cancer	2.96e-05	0.000533	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—NRAS—uterine cancer	2.95e-05	0.000532	CbGpPWpGaD
Vardenafil—PDE1B—Disease—EP300—uterine cancer	2.91e-05	0.000525	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TP53—uterine cancer	2.88e-05	0.000519	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—HRAS—uterine cancer	2.83e-05	0.000509	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—PIK3CA—uterine cancer	2.81e-05	0.000507	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—KRAS—uterine cancer	2.78e-05	0.000501	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—HRAS—uterine cancer	2.76e-05	0.000496	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—AKT1—uterine cancer	2.73e-05	0.000492	CbGpPWpGaD
Vardenafil—PDE1B—Disease—NRAS—uterine cancer	2.73e-05	0.000491	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—AKR1B1—uterine cancer	2.57e-05	0.000464	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—STAR—uterine cancer	2.57e-05	0.000464	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PIK3CA—uterine cancer	2.56e-05	0.00046	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—KRAS—uterine cancer	2.54e-05	0.000458	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—ERBB2—uterine cancer	2.51e-05	0.000452	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—AKT1—uterine cancer	2.5e-05	0.00045	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—CYP19A1—uterine cancer	2.44e-05	0.000439	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—STK11—uterine cancer	2.44e-05	0.000439	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—AKT1—uterine cancer	2.43e-05	0.000438	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CXCL8—uterine cancer	2.38e-05	0.000429	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—HRAS—uterine cancer	2.36e-05	0.000426	CbGpPWpGaD
Vardenafil—PDE1B—Disease—KRAS—uterine cancer	2.35e-05	0.000423	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PIK3CA—uterine cancer	2.34e-05	0.000421	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CDKN1B—uterine cancer	2.32e-05	0.000419	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—AKT1—uterine cancer	2.3e-05	0.000414	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CTNNB1—uterine cancer	2.2e-05	0.000396	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—HRAS—uterine cancer	2.16e-05	0.000389	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PIK3CA—uterine cancer	2.16e-05	0.000388	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PTEN—uterine cancer	2.14e-05	0.000386	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—AKT1—uterine cancer	2.09e-05	0.000376	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—EP300—uterine cancer	2.04e-05	0.000368	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—POLD1—uterine cancer	2.02e-05	0.000364	CbGpPWpGaD
Vardenafil—PDE1B—Disease—HRAS—uterine cancer	1.99e-05	0.000359	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—VEGFA—uterine cancer	1.93e-05	0.000348	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NRAS—uterine cancer	1.91e-05	0.000344	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—AKT1—uterine cancer	1.91e-05	0.000344	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.89e-05	0.00034	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—MTHFR—uterine cancer	1.83e-05	0.00033	CbGpPWpGaD
Vardenafil—PDE1B—Disease—AKT1—uterine cancer	1.76e-05	0.000317	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—RRM2—uterine cancer	1.68e-05	0.000303	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—KRAS—uterine cancer	1.64e-05	0.000296	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—DCN—uterine cancer	1.64e-05	0.000295	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CYP11A1—uterine cancer	1.54e-05	0.000278	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PIK3CA—uterine cancer	1.51e-05	0.000272	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TP53—uterine cancer	1.46e-05	0.000263	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.45e-05	0.000262	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—HRAS—uterine cancer	1.4e-05	0.000252	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—AKT1—uterine cancer	1.23e-05	0.000222	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—STK11—uterine cancer	1.13e-05	0.000204	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.13e-05	0.000204	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PTEN—uterine cancer	1.02e-05	0.000184	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—EP300—uterine cancer	9.72e-06	0.000175	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—MTHFR—uterine cancer	8.52e-06	0.000153	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PIK3CA—uterine cancer	7.19e-06	0.00013	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—AKT1—uterine cancer	5.87e-06	0.000106	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PTEN—uterine cancer	4.74e-06	8.54e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—EP300—uterine cancer	4.52e-06	8.14e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PIK3CA—uterine cancer	3.34e-06	6.02e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—AKT1—uterine cancer	2.73e-06	4.92e-05	CbGpPWpGaD
